Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Primary Breast Cancer

Autor: Thomas Bachelot, Paul Cottu, Sylvie Chabaud, Florence Dalenc, Djelila Allouache, Suzette Delaloge, Jean-Philippe Jacquin, Julien Grenier, Laurence Venat Bouvet, Apurna Jegannathen, Mario Campone, Francesco Del Piano, Marc Debled, Anne-Claire Hardy-Bessard, Sylvie Giacchetti, Marie-Ange Mouret-Reynier, Philippe Barthelemy, Laure Kaluzinski, Audrey Mailliez, Eric Legouffe, Matthew Sephton, Judith Bliss, Jean-Luc Canon, Frederique Penault-Llorca, Jerome Lemonnier, David Cameron, Fabrice Andre

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2022, 40 (32), pp.3699-3708. ⟨10.1200/JCO.21.02179⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, In press, ⟨10.1200/JCO.21.02179⟩
Bachelot, T, Cottu, P, Chabaud, S, Dalenc, F, Allouache, D, Delaloge, S, Jacquin, J-P, Grenier, J, Venat Bouvet, L, Jegannathen, A, Campone, M, Del Piano, F, Debled, M, Hardy-Bessard, A-C, Giacchetti, S, Mouret-Reynier, M-A, Barthelemy, P, Kaluzinski, L, Mailliez, A, Legouffe, E, Sephton, M, Bliss, J, Canon, J-L, Penault-Llorca, F, Lemonnier, J, Cameron, D A & Andre, F 2022, ' Everolimus added to adjuvant endocrine therapy in patients with high-risk hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer ', Journal of Clinical Oncology, vol. 386, JCO.21.02179 . https://doi.org/10.1200/JCO.21.02179, https://doi.org/10.1200/JCO.21.02179

PURPOSE Everolimus, an oral inhibitor of the mammalian target of rapamycin, improves progression-free survival in combination with endocrine therapy (ET) in postmenopausal women with aromatase inhibitor–resistant metastatic breast cancer. However,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::574c2bb7629f4cc70b7bae1bbc69bd0b
https://hal.archives-ouvertes.fr/hal-03857432

Analysis of mRNA, miRNA, and DNA in Bone Cells by RT-qPCR and In Situ Hybridization

Autor: Brice Moukengue, Jérôme Amiaud, Francois Lamoureux, Camille Jacques, Benjamin Ory, Céline Charrier

Publikováno v: Methods in molecular biology
Methods in molecular biology, 1914, pp.169-196, 2019, ⟨10.1007/978-1-4939-8997-3_9⟩
Methods in Molecular Biology ISBN: 9781493989966

International audience; The aim of this chapter is to describe a method used to evaluate gene expression and microRNAs (miRNAs) in bone cells or tissue using Reverse transcription and quantitative Polymerase Chain Reaction (RT-qPCR), and a method to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::efbb2f42bff8de6d0385b4c93cb1e9ed
https://hal.archives-ouvertes.fr/hal-03004884

Shieldin complex promotes DNA end-joining and counters homologous recombination in BRCA1-null cells

Autor: Stephen P. Jackson, Mareike Herzog, Alejandra Bruna, Luca Pellegrini, Violeta Serra, Mark J. O'Connor, Zhongwu Lai, Chloé Lescale, Jacqueline J.L. Jacobs, Fengtang Yang, Jonathan Lam, Matylda Sczaniecka-Clift, Abigail Shea, Carlos Caldas, Matthias Ostermaier, Gabriel Balmus, Julia Coates, Wenming Wei, Inge de Krijger, Yaron Galanty, Mukerrem Demir, Ludovic Deriano, Petra Beli, Domenic Pilger, Harveer Dev, Rimma Belotserkovskaya, Alistair Martin, Beiyuan Fu, Ting-Wei Will Chiang, Qian Wu

Publikováno v: Nature Cell Biology
Nature Cell Biology, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩
Nature cell biology
Nature Cell Biology, Nature Publishing Group, 2018, 20 (8), pp.954-965. ⟨10.1038/s41556-018-0140-1⟩

International audience; BRCA1 deficiencies cause breast, ovarian, prostate and other cancers, and render tumours hypersensitive to poly(ADP-ribose) polymerase (PARP) inhibitors. To understand the resistance mechanisms, we conducted whole-genome CRISP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::94c03882fb1aad0056e71d15c34e8ed4
https://www.repository.cam.ac.uk/handle/1810/282947

Single-cell functional and chemosensitive profiling of combinatorial colorectal therapy in zebrafish xenografts

Autor: Raquel V Mendes, Nuno Figueiredo, Rita Fior, Antonio S. Gomes, Miguel Godinho Ferreira, Vanda Póvoa, Tânia Carvalho

Publikováno v: Proceedings of the National Academy of Sciences of the United States of America
Proceedings of the National Academy of Sciences of the United States of America, National Academy of Sciences, 2017, 114 (39), pp.E8234-E8243. ⟨10.1073/PNAS.1618389114⟩
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
Agência para a Sociedade do Conhecimento (UMIC)-FCT-Sociedade da Informação
instacron:RCAAP

Cancer is as unique as the person fighting it. With the exception of a few biomarker-driven therapies, patients go through rounds of trial-and-error approaches to find the best treatment. Using patient-derived cell lines, we show that zebrafish larva

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d6f8760c492502f929e142ecb87f287
https://hal.archives-ouvertes.fr/hal-02438810/file/394597_2_other__4rt928.pdf

Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts

Autor: Caroline Bascoul-Mollevi, Alexandre Ho-Pun-Cheung, Bruno Robert, Frédérique Penault-Llorca, Christelle Larbouret, Isabelle Navarro-Teulon, Jean-Pierre Mach, David Azria, André Pèlegrin, Sébastien Morisseau

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2010, 21 (1), pp.98-103. ⟨10.1093/annonc/mdp496⟩
Annals of Oncology, vol. 21, no. 1, pp. 98-103

International audience; BACKGROUND: Pancreatic carcinoma remains a treatment-refractory cancer with a poor prognosis. Here, we compared anti-epidermal growth factor receptor (EGFR) and anti-HER2 monoclonal antibodies (2mAbs) injections with standard

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b9496c139250ed8d2aa60fdcb91f9bdb
http://doc.rero.ch/record/302737/files/mdp496.pdf